The company develops small molecule therapeutics for cardiovascular, metabolic, and neurodegenerative diseases, with improved safety and efficacy over existing antioxidant therapies. Genkyotex's lead product candidate, setanaxib, is a NOX inhibitor that targets NOX 1 and NOX 4, with plans to initiate a 52-week trial in primary biliary cholangitis and a Phase 2 study in head and neck cancer in 2021. Genkyotex has become a wholly owned subsidiary of Calliditas and has been delisted from the Euronext stock exchanges.